Photomicrograph of a Nerium oleander leaf.
Nerium oleander cultivation.
Robert A. Newman, Ph.D., Chief Science Officer, PBI, Inc.
Photomicrograph of human nerve cells.

Phoenix Biotechnology, Inc. (PBI)'s Focus

Phoenix Biotechnology, Inc., located in San Antonio, TX has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.

PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.

A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.

News

April, 2020
Dr. John Dye, chief of viral immunology at the USAMRIID lab at Fort Detrick, confirmed that his team began testing the extract known as oleandrin a few years ago and found it was effective in fighting the Ebola and Marburg viruses. The Army lab is now ramping up a rapid plan to test oleandrin against COVID-19.

READ ARTICLE

February, 2020
PBI sponsored research at the University of Texas at San Antonio has demonstrated that PBI-05204 leads to a marked reduction in neuroinflammtion in brain microglial cells in vitro. Importantly, when fed to mice orally the PBI drug also produces a significant reduction in accumulation of beta-amyloid plaques within the brains of specifically bred transgenic mice that develop Alzheimer’s-like disease. Taken together ,these recent findings suggest that further exploration of the utility of PBI-05204 for neurodegenerative diseases like Alzheimer's is warranted.

POSTER PRESENTATION

February, 2020
A recent 2020 publication has shown that oleandrin effectively and selectively targets human breast cancer cells without affecting normal breast epithelial cells. The selectivity is based in part on the relative content of Na,K-ATPase alpha-3 subunit as previously shown by Phoenix Biotechnology scientists.

READ PUBLICATION